The main purpose of the NOPSAD collection is to aggregate standardised jurisdictional data on the number of clients accessing pharmacotherapy for the treatment of opioid dependence, the number of prescribers participating in the delivery of pharmacotherapy treatment, and quantitative information about the prescribing sector. As such, national information on pharmacotherapy can be reported.

Collection details

Temporal coverage

from 30 June 2004 to 30 June 2018

Geographical coverage

National and state and territory

Data availability

  • Publications
  • Summary tables published in electronic form
  • Statistics
  • Client specified tables on request which may be subject to data provider approval (charges apply)
  • Unit records not available

Data scope

Covers the provision of opioid pharmacotherapy treatment, the practitioners who prescribe the treatment, the dosing sites who dispense the pharmacotherapy drugs, and the clients receiving the opioid pharmacotherapy treatment. The following pharmacotherapies are currently recommended for the treatment of opioid dependency:

  • Methadone hydrochlorideMethadone Syrup®
  • Biodone Forte ®
  • BuprenorphineSubutex®
  • Buprenorphine/NaloxoneSuboxone®.

Methodology

Admin data

Metadata information and data quality statement (DQS)

NOPSAD 2018 DQS

External links and information

NOPSAD 2018

Alcohol and Other Drug Treatment Services in Australia 2016–17   

Contact

aod@aihw.gov.au